arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Moderna, Inc.

MRNA Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$202.63
▼ -16.3% Today
as of Oct 22, 16:50 ET
Last 30 days +38.13% Sep 14 → Oct 22
$135.61 $165.20 $194.79 $224.38 $253.97 Sep 14 Sep 22 Sep 29 Oct 07 Oct 14 Oct 22
Open
$240.06
High
$241.26
Low
$180.80
Volume
$50M
Avg Vol
$12M
Mkt Cap
$78.4B
P/E (TTM)
—
Beta
—
52w High
$254.48
52w Low
$22.28
Div Yield
—
Shares Out
$399M

Recent Press Releases & News last 60 days · 25 items

mixed ▲ 0 ● 25 ▼ 0
Oct 22 · 10:14 Simply Wall St. neutral
Moderna (MRNA) Starts Late Stage Trial For mRNA Bird Flu Vaccine
Oct 22 · 05:45 Simply Wall St. neutral
Is Moderna (MRNA) Fully Valued Following Its NASDAQ 100 Inclusion?
Oct 22 · 04:01 Stocktwits neutral
Why Did MRNA, CVX, V Stocks Jump To 52-Week Highs Today?
▸ Show all 25 press releases & news Free account →

MRNA earnings at a glance

Moderna, Inc. (MRNA) is scheduled to report earnings on Thursday, November 5, 2026 — in 13 days. Analysts expect earnings per share of -$1.08, compared with -$0.51 in the same quarter last year (-112%). The options market is pricing a move of about ±4.2% after the report, a range of roughly $194.21 to $211.05 from today's $202.63. Over its last 6 reports the stock rose the next day 2 times and fell 4, moving ±4.5% on average; after the most recent report on Jul 31, 2026 it moved -5.4%. That means options currently expect about the same movement than MRNA has typically delivered. MRNA beat the consensus EPS estimate in 5 of its last 6 reported quarters. Implied volatility is currently 100%. The share price of $202.63 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$22
$254
78% of range
Avg surprise (last 6)
+33.1%
Avg reaction (last 6)
-1.7%
33% positive
Latest IV / EM
100%
EM ±4.2% · $195 · Oct 9

Earnings trends

EPS — actual vs estimate Actual Estimate
$-9.53$-7.10$-4.67$-2.24$0.19 Actual $0.19Actual $-3.62Actual $-9.53Actual $-3.07Actual $-3.33Actual $0.03Actual $-2.52Est $-2.92Actual $-2.13Est $-2.99Actual $-0.51Est $-2.15Actual $-2.11Est $-2.60Actual $-1.18Est $-3.02Actual $-1.97Est $-1.97 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258K8KJun/2026
Revenue vs Net Income Revenue Net income
$-1.3B$-518M$306M$1.1B$2.0B Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Fri Jul 31, 2026Jun/2026 $-1.97 $-1.97 0.0% +7.5% -5.4% earnings
Fri May 1, 20268K 2026-05-01 $-1.18 $-3.02 +60.9% — -1.2% earnings
Fri Feb 13, 20268K 2026-02-13 $-2.11 $-2.60 +18.9% — +5.3% earnings
Thu Nov 6, 2025Sep/2025 $-0.51 $-2.15 +76.3% — +3.3% earnings
Fri Aug 1, 2025Jun/2025 $-2.13 $-2.99 +28.8% — -6.6% earnings
Thu May 1, 2025Mar/2025 $-2.52 $-2.92 +13.7% — -5.3% earnings
Mon Sep 30, 2024Sep 2024 $0.03 — — — — financials
Sun Jun 30, 2024Jun 2024 $-3.33 — — — — financials
Sun Mar 31, 2024Mar 2024 $-3.07 — — — — financials
Sat Sep 30, 2023Sep 2023 $-9.53 — — — — financials
Fri Jun 30, 2023Jun 2023 $-3.62 — — — — financials
Fri Mar 31, 2023Mar 2023 $0.19 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Thu Nov 5, 2026Sep/2026OTHER -$1.08-$0.51 -111.8%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$145M$389M—$1.02B$142M$108M—$1.86B
Cost of revenue$93M$955M—$207M$119M$90M—$514M
Gross profit————————
Operating income$-815M$-1.39B—$-260M$-907M$-1.05B—$-70M
Net income$-782M$-1.34B—$-200M$-825M$-971M—$13M
EPS (diluted)$-1.97$-3.40—$-0.51$-2.13$-2.52—$0.03

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$1.72B$1.91B$2.60B$1.13B$1.28B$1.62B$1.93B$1.64B
Inventory$280M$146M$153M$332M$240M$128M$117M$412M
Total current assets$5.82B$5.77B$6.54B$6.60B$6.17B$6.77B$8.10B$9.67B
Total assets$10.96B$11.49B$12.34B$12.13B$12.01B$12.70B$14.14B$15.80B
Long-term debt$591M$590M$590M—————
Total liabilities$4.20B$4.08B$3.69B$2.81B$2.61B$2.64B$3.24B$3.88B
Total equity$6.76B$7.41B$8.65B$9.33B$9.40B$10.07B$10.90B$11.93B

Implied volatility — last 90 days

69%120%171%222%272% Jun 07 — IV 88% · EM ±8.2%Jun 08 — IV 82% · EM ±6.9%Jun 09 — IV 82% · EM ±5.9%Jun 10 — IV 89% · EM ±5.3%Jun 11 — IV 85% · EM ±3.5%Jun 15 — IV 80% · EM ±5.8%Jun 16 — IV 96% · EM ±5.7%Jun 17 — IV 130% · EM ±5.4%Jun 19 — IV 95% · EM ±10.5%Jun 22 — IV 92% · EM ±7.7%Jun 23 — IV 91% · EM ±6.6%Jun 24 — IV 90% · EM ±5.3%Jun 25 — IV 89% · EM ±3.7%Jun 29 — IV 92% · EM ±21.8%Jun 30 — IV 88% · EM ±20.4%Jul 01 — IV 87% · EM ±3.6%Jul 03 — IV 92% · EM ±10.2%Jul 06 — IV 103% · EM ±8.6%Jul 07 — IV 104% · EM ±7.5%Jul 08 — IV 98% · EM ±5.8%Jul 09 — IV 100% · EM ±4.2%Jul 13 — IV 88% · EM ±7.4%Jul 14 — IV 82% · EM ±5.9%Jul 15 — IV 90% · EM ±5.3%Jul 16 — IV 89% · EM ±3.7%Jul 20 — IV 80% · EM ±6.7%Jul 21 — IV 84% · EM ±6.1%Jul 22 — IV 86% · EM ±5.1%Jul 23 — IV 82% · EM ±3.4%Jul 27 — IV 127% · EM ±10.6%Jul 28 — IV 129% · EM ±9.3%Jul 29 — IV 163% · EM ±9.7%Jul 30 — IV 188% · EM ±7.9%Aug 03 — IV 95% · EM ±7.9%Aug 04 — IV 87% · EM ±6.3%Aug 05 — IV 87% · EM ±5.2%Aug 06 — IV 73% · EM ±3.1%Aug 10 — IV 77% · EM ±6.4%Aug 11 — IV 83% · EM ±6.0%Aug 12 — IV 74% · EM ±4.3%Aug 13 — IV 79% · EM ±3.3%Aug 17 — IV 70% · EM ±5.8%Aug 18 — IV 78% · EM ±5.6%Aug 19 — IV 273% · EM ±16.1%Aug 20 — IV 208% · EM ±8.7%Aug 24 — IV 125% · EM ±10.5%Aug 25 — IV 137% · EM ±9.9%Aug 26 — IV 109% · EM ±6.4%Aug 27 — IV 95% · EM ±4.0%Aug 31 — IV 95% · EM ±7.9%Sep 01 — IV 101% · EM ±7.3%Sep 02 — IV 92% · EM ±5.4%Sep 03 — IV 91% · EM ±3.8%Sep 07 — IV 87% · EM ±7.3%Sep 08 — IV 77% · EM ±5.6%Sep 09 — IV 74% · EM ±4.4%Sep 10 — IV 75% · EM ±3.1%Sep 14 — IV 85% · EM ±7.1%Sep 15 — IV 83% · EM ±6.0%Sep 16 — IV 87% · EM ±5.1%Sep 17 — IV 89% · EM ±3.7%Sep 21 — IV 86% · EM ±7.2%Sep 22 — IV 82% · EM ±6.0%Sep 23 — IV 86% · EM ±5.1%Sep 24 — IV 91% · EM ±3.8%Sep 28 — IV 101% · EM ±23.8%Sep 29 — IV 102% · EM ±23.7%Sep 30 — IV 91% · EM ±5.4%Oct 01 — IV 93% · EM ±3.9%Oct 06 — IV 93% · EM ±6.7%Oct 07 — IV 91% · EM ±5.4%Oct 08 — IV 100% · EM ±4.2%

Sector peers

ARGX
argenx SE
$57.6B $875.76+0.7%
RVMD
Revolution Medicines, Inc.
$43.1B $187.69-4.5%
BIIB
Biogen Inc.
$32.8B $253.84+4.4%
BNTX
BioNTech SE
$23.9B $89.67-1.6%
NBIX
Neurocrine Biosciences, Inc.
$14.6B $143.29+0.9%
EXEL
Exelixis, Inc.
$14.5B $65.31+1.4%

MRNA earnings FAQ

When is MRNA's next earnings date?

Moderna, Inc. is expected to report on November 5, 2026.

What is MRNA's expected move for earnings?

Options currently price a move of about ±4.2%, or $8.42 per share either way from $202.63.

How does MRNA stock usually react to earnings?

Across the last 6 reports the average next-day move was ±4.5%, up 2 times and down 4 times.

What EPS are analysts expecting from Moderna, Inc.?

The consensus estimate is -$1.08 per share, versus -$0.51 a year ago.

What is MRNA's implied volatility?

MRNA's at-the-money implied volatility is about 100% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in